70-Gene signature as an aid to treatment decisions in early-stage breast cancer

New England Journal of Medicine

Volumn 375, Issue 8, 2016, Pages 717-729

  Cardoso, Fatima ^a   Van't Veer, L J ^b   Bogaerts, J ^c   Slaets, L ^c   Viale, G ^f   Delaloge, S ⁱ   Pierga, J Y ^j   Brain, E ^k   Causeret, S ^l   DeLorenzi, M ^m   Glas, A M ⁿ   Golfinopoulos, V ^c   Goulioti, T ^c   Knox, S ^g   Matos, E ^s   Meulemans, B ^c   Neijenhuis, P A ^p   Nitz, U ^t   Passalacqua, R ^h   Ravdin, P ^u   Rubio, I T ^v   Saghatchian, M ⁱ   Smilde, T J ^q   Sotiriou, C ^d   Stork, L ⁿ   Straehle, C ^c   Thomas, G ^w   Thompson, A M ^x   Van Der Hoeven, J M ^r   Vuylsteke, P ^e   Bernards, R ^o   Tryfonidis, K ^c   Rutgers, E ^o   Piccart, M ^d   more..

^a CHAMPALIMAUD CLINICAL CENTER   (Portugal)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^d JULES BORDET INSTITUTE   (Belgium)

^e UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^f UNIVERSITY OF MILAN   (Italy)

^g Europa Donna: the European Breast Cancer Coalition   (Italy)

^h CREMONA HOSPITAL   (Italy)

ⁱ INSTITUT GUSTAVE ROUSSY   (France)

^j PSL RESEARCH UNIVERSITY   (France)

^k INSTITUT CURIE   (France)

^l CENTRE GEORGES FRANÇOIS LECLERC   (France)

^m UNIVERSITY OF LAUSANNE   (Switzerland)

ⁿ Agendia NV   (Netherlands)

^o NETHERLANDS CANCER INSTITUTE   (Netherlands)

^p ALRIJNE HOSPITAL   (Netherlands)

^q JEROEN BOSCH HOSPITAL   (Netherlands)

^r Medical Centre Alkmaar   (Netherlands)

^s INSTITUTE OF ONCOLOGY   (Slovenia)

^t Ev Krankenhaus Bethesda   (Germany)

^u UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^v HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^w IMPERIAL COLLEGE LONDON   (United Kingdom)

^x UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; ONCOGENE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; BREAST NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DNA MICROARRAY; GENE EXPRESSION; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; KAPLAN MEIER METHOD; MASTECTOMY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NEOPLASM METASTASIS; RISK; RISK ASSESSMENT;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; KAPLAN-MEIER ESTIMATE; MASTECTOMY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSPECTIVE STUDIES; RISK; RISK ASSESSMENT;

EID: 84984697640     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1602253     Document Type: Article

References (24)

1. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 2015;26:1533-46.
2. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980-91.
3. Olivotto IA, Bajdik CD, Ravdin PM, et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:2716-25.
4. Wishart GC, Bajdik CD, Dicks E, et al. PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer 2012;107:800-7.
5. Oakman C, Santarpia L, Di Leo A. Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol 2010;7:725-32.
6. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G. International Web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 2007;9(6):R81.
7. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
8. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009;360:790-800.
9. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
10. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
11. van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
12. Buyse M, Loi S, van't Veer L, et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92.
13. Hayes DF. Biomarker validation and testing. Mol Oncol 2015;9:960-6.
14. Hayes DF, Bast RC, Desch CE, et al. Tumor Marker Utility Grading System: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
15. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52.
16. Bogaerts J, Cardoso F, Buyse M, et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol 2006;3:540-51.
17. Cardoso F, Van 't Veer L, Rutgers E, Loi S, Mook S, Piccart-Gebhart MJ. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008;26:729-35.
18. Mook S, Schmidt MK, Viale G, et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009;116:295-302.
19. Mook S, Bonnefoi H, Pruneri G, et al. Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur J Cancer 2009;45:1201-8.
20. Beumer I, Witteveen A, Delahaye L, et al. Equivalence of MammaPrint array types in clinical trials and diagnostics. Breast Cancer Res Treat 2016;156:279-87.
21. Rutgers E, Piccart-Gebhart MJ, Bogaerts J, et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011;47:2742-9.
22. Viale G, Slaets L, Bogaerts J, et al. High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol 2014;25:816-23.
23. Viale G, Slaets L, de Snoo FA, et al. Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance. Breast Cancer Res Treat 2016;155:463-9.
24. Early Breast Cancer Trialists' Collaborative Group. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44.